Plasma proteome of Long-COVID patients indicates HIF-mediated vasculo-proliferative disease with impact on brain and heart function

Long-COVID occurs after SARS-CoV-2 infection and results in diverse, prolonged symptoms. The present study aimed to unveil potential mechanisms, and to inform prognosis and treatment. Plasma proteome from Long-COVID outpatients was analyzed in comparison to matched acutely ill COVID-19 (mild and sev...

Full description

Saved in:
Bibliographic Details
Published inJournal of translational medicine Vol. 21; no. 1; pp. 377 - 21
Main Authors Iosef, Cristiana, Knauer, Michael J., Nicholson, Michael, Van Nynatten, Logan R., Cepinskas, Gediminas, Draghici, Sorin, Han, Victor K. M., Fraser, Douglas D.
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 10.06.2023
BioMed Central
BMC
Subjects
Analysis
Angiopoietin
Angiotensin
Bioinformatics
Biomarkers
Brain
CD56 antigen
Chemokines
Citrulline
Clustering
COVID-19
Disease
Elastase
Genes
Genetic engineering
Geospatial data
Histones
Humans
Hypoxia
Infections
Laboratories
Leukocytes (neutrophilic)
Long COVID
Medical research
Natural killer cells
Neutrophils
Phenotypes
Plasma
Post-Acute COVID-19 Syndrome
Prospective Studies
Protein expression
Proteins
Proteome
Proteomes
Proteomics
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Signal transduction
Software
Therapeutic targets
Vascular endothelial growth factor
United States
Online AccessGet full text
ISSN1479-5876
1479-5876
DOI10.1186/s12967-023-04149-9

Cover

Abstract Long-COVID occurs after SARS-CoV-2 infection and results in diverse, prolonged symptoms. The present study aimed to unveil potential mechanisms, and to inform prognosis and treatment. Plasma proteome from Long-COVID outpatients was analyzed in comparison to matched acutely ill COVID-19 (mild and severe) inpatients and healthy control subjects. The expression of 3072 protein biomarkers was determined with proximity extension assays and then deconvoluted with multiple bioinformatics tools into both cell types and signaling mechanisms, as well as organ specificity. Compared to age- and sex-matched acutely ill COVID-19 inpatients and healthy control subjects, Long-COVID outpatients showed natural killer cell redistribution with a dominant resting phenotype, as opposed to active, and neutrophils that formed extracellular traps. This potential resetting of cell phenotypes was reflected in prospective vascular events mediated by both angiopoietin-1 (ANGPT1) and vascular-endothelial growth factor-A (VEGFA). Several markers (ANGPT1, VEGFA, CCR7, CD56, citrullinated histone 3, elastase) were validated by serological methods in additional patient cohorts. Signaling of transforming growth factor-β1 with probable connections to elevated EP/p300 suggested vascular inflammation and tumor necrosis factor-α driven pathways. In addition, a vascular proliferative state associated with hypoxia inducible factor 1 pathway suggested progression from acute COVID-19 to Long-COVID. The vasculo-proliferative process predicted in Long-COVID might contribute to changes in the organ-specific proteome reflective of neurologic and cardiometabolic dysfunction. Taken together, our findings point to a vasculo-proliferative process in Long-COVID that is likely initiated either prior hypoxia (localized or systemic) and/or stimulatory factors (i.e., cytokines, chemokines, growth factors, angiotensin, etc). Analyses of the plasma proteome, used as a surrogate for cellular signaling, unveiled potential organ-specific prognostic biomarkers and therapeutic targets.
AbstractList Long-COVID occurs after SARS-CoV-2 infection and results in diverse, prolonged symptoms. The present study aimed to unveil potential mechanisms, and to inform prognosis and treatment. Plasma proteome from Long-COVID outpatients was analyzed in comparison to matched acutely ill COVID-19 (mild and severe) inpatients and healthy control subjects. The expression of 3072 protein biomarkers was determined with proximity extension assays and then deconvoluted with multiple bioinformatics tools into both cell types and signaling mechanisms, as well as organ specificity. Compared to age- and sex-matched acutely ill COVID-19 inpatients and healthy control subjects, Long-COVID outpatients showed natural killer cell redistribution with a dominant resting phenotype, as opposed to active, and neutrophils that formed extracellular traps. This potential resetting of cell phenotypes was reflected in prospective vascular events mediated by both angiopoietin-1 (ANGPT1) and vascular-endothelial growth factor-A (VEGFA). Several markers (ANGPT1, VEGFA, CCR7, CD56, citrullinated histone 3, elastase) were validated by serological methods in additional patient cohorts. Signaling of transforming growth factor-β1 with probable connections to elevated EP/p300 suggested vascular inflammation and tumor necrosis factor-α driven pathways. In addition, a vascular proliferative state associated with hypoxia inducible factor 1 pathway suggested progression from acute COVID-19 to Long-COVID. The vasculo-proliferative process predicted in Long-COVID might contribute to changes in the organ-specific proteome reflective of neurologic and cardiometabolic dysfunction. Taken together, our findings point to a vasculo-proliferative process in Long-COVID that is likely initiated either prior hypoxia (localized or systemic) and/or stimulatory factors (i.e., cytokines, chemokines, growth factors, angiotensin, etc). Analyses of the plasma proteome, used as a surrogate for cellular signaling, unveiled potential organ-specific prognostic biomarkers and therapeutic targets.
Abstract Aims Long-COVID occurs after SARS-CoV-2 infection and results in diverse, prolonged symptoms. The present study aimed to unveil potential mechanisms, and to inform prognosis and treatment. Methods Plasma proteome from Long-COVID outpatients was analyzed in comparison to matched acutely ill COVID-19 (mild and severe) inpatients and healthy control subjects. The expression of 3072 protein biomarkers was determined with proximity extension assays and then deconvoluted with multiple bioinformatics tools into both cell types and signaling mechanisms, as well as organ specificity. Results Compared to age- and sex-matched acutely ill COVID-19 inpatients and healthy control subjects, Long-COVID outpatients showed natural killer cell redistribution with a dominant resting phenotype, as opposed to active, and neutrophils that formed extracellular traps. This potential resetting of cell phenotypes was reflected in prospective vascular events mediated by both angiopoietin-1 (ANGPT1) and vascular-endothelial growth factor-A (VEGFA). Several markers (ANGPT1, VEGFA, CCR7, CD56, citrullinated histone 3, elastase) were validated by serological methods in additional patient cohorts. Signaling of transforming growth factor-β1 with probable connections to elevated EP/p300 suggested vascular inflammation and tumor necrosis factor-α driven pathways. In addition, a vascular proliferative state associated with hypoxia inducible factor 1 pathway suggested progression from acute COVID-19 to Long-COVID. The vasculo-proliferative process predicted in Long-COVID might contribute to changes in the organ-specific proteome reflective of neurologic and cardiometabolic dysfunction. Conclusions Taken together, our findings point to a vasculo-proliferative process in Long-COVID that is likely initiated either prior hypoxia (localized or systemic) and/or stimulatory factors (i.e., cytokines, chemokines, growth factors, angiotensin, etc). Analyses of the plasma proteome, used as a surrogate for cellular signaling, unveiled potential organ-specific prognostic biomarkers and therapeutic targets.
Aims Long-COVID occurs after SARS-CoV-2 infection and results in diverse, prolonged symptoms. The present study aimed to unveil potential mechanisms, and to inform prognosis and treatment. Methods Plasma proteome from Long-COVID outpatients was analyzed in comparison to matched acutely ill COVID-19 (mild and severe) inpatients and healthy control subjects. The expression of 3072 protein biomarkers was determined with proximity extension assays and then deconvoluted with multiple bioinformatics tools into both cell types and signaling mechanisms, as well as organ specificity. Results Compared to age- and sex-matched acutely ill COVID-19 inpatients and healthy control subjects, Long-COVID outpatients showed natural killer cell redistribution with a dominant resting phenotype, as opposed to active, and neutrophils that formed extracellular traps. This potential resetting of cell phenotypes was reflected in prospective vascular events mediated by both angiopoietin-1 (ANGPT1) and vascular-endothelial growth factor-A (VEGFA). Several markers (ANGPT1, VEGFA, CCR7, CD56, citrullinated histone 3, elastase) were validated by serological methods in additional patient cohorts. Signaling of transforming growth factor-[beta]1 with probable connections to elevated EP/p300 suggested vascular inflammation and tumor necrosis factor-[alpha] driven pathways. In addition, a vascular proliferative state associated with hypoxia inducible factor 1 pathway suggested progression from acute COVID-19 to Long-COVID. The vasculo-proliferative process predicted in Long-COVID might contribute to changes in the organ-specific proteome reflective of neurologic and cardiometabolic dysfunction. Conclusions Taken together, our findings point to a vasculo-proliferative process in Long-COVID that is likely initiated either prior hypoxia (localized or systemic) and/or stimulatory factors (i.e., cytokines, chemokines, growth factors, angiotensin, etc). Analyses of the plasma proteome, used as a surrogate for cellular signaling, unveiled potential organ-specific prognostic biomarkers and therapeutic targets.
Long-COVID occurs after SARS-CoV-2 infection and results in diverse, prolonged symptoms. The present study aimed to unveil potential mechanisms, and to inform prognosis and treatment.AIMSLong-COVID occurs after SARS-CoV-2 infection and results in diverse, prolonged symptoms. The present study aimed to unveil potential mechanisms, and to inform prognosis and treatment.Plasma proteome from Long-COVID outpatients was analyzed in comparison to matched acutely ill COVID-19 (mild and severe) inpatients and healthy control subjects. The expression of 3072 protein biomarkers was determined with proximity extension assays and then deconvoluted with multiple bioinformatics tools into both cell types and signaling mechanisms, as well as organ specificity.METHODSPlasma proteome from Long-COVID outpatients was analyzed in comparison to matched acutely ill COVID-19 (mild and severe) inpatients and healthy control subjects. The expression of 3072 protein biomarkers was determined with proximity extension assays and then deconvoluted with multiple bioinformatics tools into both cell types and signaling mechanisms, as well as organ specificity.Compared to age- and sex-matched acutely ill COVID-19 inpatients and healthy control subjects, Long-COVID outpatients showed natural killer cell redistribution with a dominant resting phenotype, as opposed to active, and neutrophils that formed extracellular traps. This potential resetting of cell phenotypes was reflected in prospective vascular events mediated by both angiopoietin-1 (ANGPT1) and vascular-endothelial growth factor-A (VEGFA). Several markers (ANGPT1, VEGFA, CCR7, CD56, citrullinated histone 3, elastase) were validated by serological methods in additional patient cohorts. Signaling of transforming growth factor-β1 with probable connections to elevated EP/p300 suggested vascular inflammation and tumor necrosis factor-α driven pathways. In addition, a vascular proliferative state associated with hypoxia inducible factor 1 pathway suggested progression from acute COVID-19 to Long-COVID. The vasculo-proliferative process predicted in Long-COVID might contribute to changes in the organ-specific proteome reflective of neurologic and cardiometabolic dysfunction.RESULTSCompared to age- and sex-matched acutely ill COVID-19 inpatients and healthy control subjects, Long-COVID outpatients showed natural killer cell redistribution with a dominant resting phenotype, as opposed to active, and neutrophils that formed extracellular traps. This potential resetting of cell phenotypes was reflected in prospective vascular events mediated by both angiopoietin-1 (ANGPT1) and vascular-endothelial growth factor-A (VEGFA). Several markers (ANGPT1, VEGFA, CCR7, CD56, citrullinated histone 3, elastase) were validated by serological methods in additional patient cohorts. Signaling of transforming growth factor-β1 with probable connections to elevated EP/p300 suggested vascular inflammation and tumor necrosis factor-α driven pathways. In addition, a vascular proliferative state associated with hypoxia inducible factor 1 pathway suggested progression from acute COVID-19 to Long-COVID. The vasculo-proliferative process predicted in Long-COVID might contribute to changes in the organ-specific proteome reflective of neurologic and cardiometabolic dysfunction.Taken together, our findings point to a vasculo-proliferative process in Long-COVID that is likely initiated either prior hypoxia (localized or systemic) and/or stimulatory factors (i.e., cytokines, chemokines, growth factors, angiotensin, etc). Analyses of the plasma proteome, used as a surrogate for cellular signaling, unveiled potential organ-specific prognostic biomarkers and therapeutic targets.CONCLUSIONSTaken together, our findings point to a vasculo-proliferative process in Long-COVID that is likely initiated either prior hypoxia (localized or systemic) and/or stimulatory factors (i.e., cytokines, chemokines, growth factors, angiotensin, etc). Analyses of the plasma proteome, used as a surrogate for cellular signaling, unveiled potential organ-specific prognostic biomarkers and therapeutic targets.
Long-COVID occurs after SARS-CoV-2 infection and results in diverse, prolonged symptoms. The present study aimed to unveil potential mechanisms, and to inform prognosis and treatment. Plasma proteome from Long-COVID outpatients was analyzed in comparison to matched acutely ill COVID-19 (mild and severe) inpatients and healthy control subjects. The expression of 3072 protein biomarkers was determined with proximity extension assays and then deconvoluted with multiple bioinformatics tools into both cell types and signaling mechanisms, as well as organ specificity. Compared to age- and sex-matched acutely ill COVID-19 inpatients and healthy control subjects, Long-COVID outpatients showed natural killer cell redistribution with a dominant resting phenotype, as opposed to active, and neutrophils that formed extracellular traps. This potential resetting of cell phenotypes was reflected in prospective vascular events mediated by both angiopoietin-1 (ANGPT1) and vascular-endothelial growth factor-A (VEGFA). Several markers (ANGPT1, VEGFA, CCR7, CD56, citrullinated histone 3, elastase) were validated by serological methods in additional patient cohorts. Signaling of transforming growth factor-[beta]1 with probable connections to elevated EP/p300 suggested vascular inflammation and tumor necrosis factor-[alpha] driven pathways. In addition, a vascular proliferative state associated with hypoxia inducible factor 1 pathway suggested progression from acute COVID-19 to Long-COVID. The vasculo-proliferative process predicted in Long-COVID might contribute to changes in the organ-specific proteome reflective of neurologic and cardiometabolic dysfunction. Taken together, our findings point to a vasculo-proliferative process in Long-COVID that is likely initiated either prior hypoxia (localized or systemic) and/or stimulatory factors (i.e., cytokines, chemokines, growth factors, angiotensin, etc). Analyses of the plasma proteome, used as a surrogate for cellular signaling, unveiled potential organ-specific prognostic biomarkers and therapeutic targets.
AimsLong-COVID occurs after SARS-CoV-2 infection and results in diverse, prolonged symptoms. The present study aimed to unveil potential mechanisms, and to inform prognosis and treatment.MethodsPlasma proteome from Long-COVID outpatients was analyzed in comparison to matched acutely ill COVID-19 (mild and severe) inpatients and healthy control subjects. The expression of 3072 protein biomarkers was determined with proximity extension assays and then deconvoluted with multiple bioinformatics tools into both cell types and signaling mechanisms, as well as organ specificity.ResultsCompared to age- and sex-matched acutely ill COVID-19 inpatients and healthy control subjects, Long-COVID outpatients showed natural killer cell redistribution with a dominant resting phenotype, as opposed to active, and neutrophils that formed extracellular traps. This potential resetting of cell phenotypes was reflected in prospective vascular events mediated by both angiopoietin-1 (ANGPT1) and vascular-endothelial growth factor-A (VEGFA). Several markers (ANGPT1, VEGFA, CCR7, CD56, citrullinated histone 3, elastase) were validated by serological methods in additional patient cohorts. Signaling of transforming growth factor-β1 with probable connections to elevated EP/p300 suggested vascular inflammation and tumor necrosis factor-α driven pathways. In addition, a vascular proliferative state associated with hypoxia inducible factor 1 pathway suggested progression from acute COVID-19 to Long-COVID. The vasculo-proliferative process predicted in Long-COVID might contribute to changes in the organ-specific proteome reflective of neurologic and cardiometabolic dysfunction.ConclusionsTaken together, our findings point to a vasculo-proliferative process in Long-COVID that is likely initiated either prior hypoxia (localized or systemic) and/or stimulatory factors (i.e., cytokines, chemokines, growth factors, angiotensin, etc). Analyses of the plasma proteome, used as a surrogate for cellular signaling, unveiled potential organ-specific prognostic biomarkers and therapeutic targets.
ArticleNumber 377
Audience Academic
Author Cepinskas, Gediminas
Nicholson, Michael
Draghici, Sorin
Iosef, Cristiana
Van Nynatten, Logan R.
Knauer, Michael J.
Han, Victor K. M.
Fraser, Douglas D.
Author_xml – sequence: 1
  givenname: Cristiana
  surname: Iosef
  fullname: Iosef, Cristiana
– sequence: 2
  givenname: Michael J.
  surname: Knauer
  fullname: Knauer, Michael J.
– sequence: 3
  givenname: Michael
  surname: Nicholson
  fullname: Nicholson, Michael
– sequence: 4
  givenname: Logan R.
  surname: Van Nynatten
  fullname: Van Nynatten, Logan R.
– sequence: 5
  givenname: Gediminas
  surname: Cepinskas
  fullname: Cepinskas, Gediminas
– sequence: 6
  givenname: Sorin
  surname: Draghici
  fullname: Draghici, Sorin
– sequence: 7
  givenname: Victor K. M.
  surname: Han
  fullname: Han, Victor K. M.
– sequence: 8
  givenname: Douglas D.
  surname: Fraser
  fullname: Fraser, Douglas D.
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37301958$$D View this record in MEDLINE/PubMed
BookMark eNp9kktv1DAUhSNURB_wB1ggS2zYpMTP2CtUDZSONFJZAFvrxnZmXCX2ECdTseaP43Ra6FQIeWHn5pwvvjfntDgKMbiieI2rc4yleJ8wUaIuK0LLimGmSvWsOMGsViWXtTh6dD4uTlO6qSrCOFMvimNa0worLk-KX186SD2g7RBHF3uHYotWMazLxfX35Ue0hdG7MCbkg_UGRpfQ1fKy7J31-cGiHSQzdbHM9s63bsjynUPWJwfJoVs_bpDvt2BGFANqBvABQbBo42AYUTsFM_oYXhbPW-iSe3W_nxXfLj99XVyVq-vPy8XFqjRcsLEE5UA4zlurlLTY0KZ1ljW4rbmRQnLgljNcY1tJShuwqla2MY2rKAVrKKVnxXLPtRFu9HbwPQw_dQSv7wpxWOt8LW86pxnmdYOJE4IqZomRikHbVA1IKy2xJLM-7FnbqcnTMHlIA3QH0MM3wW_0Ou40rgivqZwJ7-4JQ_wxuTTq3ifjug6Ci1PSRBImFMeUZ-nbJ9KbOA0hz2pW1RjXguC_qjXkDnxoY_6wmaH6ouaECyHwPITzf6jysq73Jges9bl-YHjzuNM_LT5kKAvkXmCGmNLgWm38CPOPzWTf5Y71HFe9j6vOcdV3cdUqW8kT6wP9P6bf-STtZA
CitedBy_id crossref_primary_10_1093_qjmed_hcaf050
crossref_primary_10_1186_s10020_024_00898_5
crossref_primary_10_3390_biomedicines12122893
crossref_primary_10_1111_all_16526
crossref_primary_10_3389_fendo_2024_1459724
crossref_primary_10_3390_biom13111597
crossref_primary_10_7759_cureus_44888
crossref_primary_10_1016_j_jiph_2024_102571
crossref_primary_10_1016_j_jacc_2024_11_044
crossref_primary_10_1038_s41591_024_03173_6
crossref_primary_10_1016_j_isci_2024_110839
crossref_primary_10_3389_fcimb_2023_1216176
crossref_primary_10_1089_vim_2023_0116
crossref_primary_10_3389_fimmu_2024_1341843
crossref_primary_10_3389_fneur_2024_1465787
crossref_primary_10_1016_j_bbi_2024_10_032
crossref_primary_10_1038_s41590_024_01778_0
crossref_primary_10_1016_j_saa_2024_125474
crossref_primary_10_1126_scitranslmed_ado2106
crossref_primary_10_3390_ijms25168633
crossref_primary_10_1186_s10020_024_00806_x
crossref_primary_10_1007_s40291_024_00731_z
crossref_primary_10_1007_s10238_024_01545_3
crossref_primary_10_1002_jmv_29887
crossref_primary_10_1021_acs_jproteome_4c00536
Cites_doi 10.1111/jcmm.17622
10.1038/s41591-019-0665-2
10.1038/s41467-022-30932-1
10.1038/s42255-021-00425-4
10.1126/science.abc8511
10.1038/s41586-021-04142-6
10.1016/j.autrev.2022.103071
10.1038/d41586-022-02140-w
10.1097/CCE.0000000000000369
10.1007/s00415-021-10655-x
10.1097/CCE.0000000000000144
10.1016/S0140-6736(22)00941-2
10.1189/jlb.71.2.173
10.1016/j.immuni.2022.01.017
10.3389/fgene.2019.00159
10.1186/s10020-023-00610-z
10.1002/rmv.2315
10.1093/nar/gky1131
10.1080/07853890.2022.2076901
10.1038/s41591-020-1038-6
10.3389/fimmu.12:810286.10.3389/fimmu.2021.810286
10.1136/bcr-2020-241485
10.1186/s12933-022-01623-4
10.1016/j.immuni.2020.10.008
10.1186/s12931-020-01462-5
10.1073/pnas.1821565116
10.1126/science.abc6261
10.3389/fcell.2022.807149
10.1016/j.isci.2022.105717
10.1038/s41591-022-01689-3
10.1016/j.smim.2022.101602
10.1126/science.ada0536
10.3389/fphys.2021.745634
10.1016/j.xcrm.2022.100680
10.1016/j.cell.2022.01.014
10.15252/emmm.202114532
10.1002/prca.202200031
10.1186/s10020-022-00548-8
10.1038/s41467-022-28639-4
10.1093/nar/gkr424
10.1093/nar/gkac488
10.1038/s41591-021-01329-2
10.1038/s41586-021-03553-9
10.1016/j.xcrm.2021.100287
10.3389/fcvm.2021.652584
10.1016/S1473-3099(20)30120-1
10.1038/s41591-020-0944-y
10.1097/MOH.0000000000000361
10.3389/fimmu.2021.746021
10.1182/bloodadvances.2020003568
10.1016/S2589-7500(22)00048-6
10.1038/s41591-021-01283-z
10.1007/s10549-017-4633-6
10.1097/CCE.0000000000000189
10.3389/fimmu.2021.700782
10.1101/2022.03.23.22272828
10.1016/S1474-4422(20)30221-0
10.1038/nmeth.3337
10.1038/s41591-021-01576-3
10.1182/blood-2008-08-172742
10.1016/j.gendis.2021.08.004
10.1038/s41598-020-60981-9
10.1016/j.cels.2021.05.005
10.1101/gr.6202607
10.1016/j.cell.2020.08.002
10.1001/jamapsychiatry.2021.0500
10.1038/onc.2012.191
10.1038/s41586-018-0175-2
10.1038/s41591-022-01840-0
10.1186/s12885-020-07573-y
10.3390/s23052473
ContentType Journal Article
Copyright 2023. The Author(s).
COPYRIGHT 2023 BioMed Central Ltd.
2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2023
Copyright_xml – notice: 2023. The Author(s).
– notice: COPYRIGHT 2023 BioMed Central Ltd.
– notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2023
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7T5
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
COVID
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12967-023-04149-9
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Immunology Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
Coronavirus Research Database
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic
ProQuest Publicly Available Content
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE


MEDLINE - Academic

Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: Open Access: DOAJ - Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: AUTh Library subscriptions: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1479-5876
EndPage 21
ExternalDocumentID oai_doaj_org_article_4157b12e66394d2c894afb0ba8d8d2d2
PMC10257382
A752566613
37301958
10_1186_s12967_023_04149_9
Genre Journal Article
GeographicLocations United States
GeographicLocations_xml – name: United States
GrantInformation_xml – fundername: Academic Medical Organization of Southwestern Ontario
  grantid: INNO20-029
– fundername: ;
  grantid: INNO20-029
GroupedDBID ---
0R~
29L
2WC
53G
5VS
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
TR2
TUS
UKHRP
WOQ
WOW
XSB
~8M
-A0
3V.
ACRMQ
ADINQ
C24
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
7T5
7XB
8FK
AZQEC
COVID
DWQXO
H94
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c564t-a9ea6e55fd998d1c3bfed4b1f75c8685a5d54171d0833bad979dbcbe033adc333
IEDL.DBID M48
ISSN 1479-5876
IngestDate Wed Aug 27 01:06:51 EDT 2025
Thu Aug 21 18:37:41 EDT 2025
Fri Jul 11 10:03:44 EDT 2025
Fri Jul 25 23:01:23 EDT 2025
Tue Jun 17 21:33:00 EDT 2025
Tue Jun 10 20:11:35 EDT 2025
Thu Jan 02 22:52:40 EST 2025
Thu Apr 24 23:00:59 EDT 2025
Tue Jul 01 02:59:40 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License 2023. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c564t-a9ea6e55fd998d1c3bfed4b1f75c8685a5d54171d0833bad979dbcbe033adc333
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12967-023-04149-9
PMID 37301958
PQID 2827117621
PQPubID 43076
PageCount 21
ParticipantIDs doaj_primary_oai_doaj_org_article_4157b12e66394d2c894afb0ba8d8d2d2
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10257382
proquest_miscellaneous_2824695135
proquest_journals_2827117621
gale_infotracmisc_A752566613
gale_infotracacademiconefile_A752566613
pubmed_primary_37301958
crossref_citationtrail_10_1186_s12967_023_04149_9
crossref_primary_10_1186_s12967_023_04149_9
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-06-10
PublicationDateYYYYMMDD 2023-06-10
PublicationDate_xml – month: 06
  year: 2023
  text: 2023-06-10
  day: 10
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Journal of translational medicine
PublicationTitleAlternate J Transl Med
PublicationYear 2023
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References B Vijayakumar (4149_CR13) 2022; 55
T Nguyen (4149_CR46) 2020; 10
MR Filbin (4149_CR23) 2021; 2
ER Pfaff (4149_CR47) 2022
S Dhont (4149_CR73) 2020; 21
P Taribagil (4149_CR17) 2021; 14
M Charnley (4149_CR64) 2022; 13
DD Fraser (4149_CR33) 2021; 3
DD Fraser (4149_CR40) 2020; 2
V Demichev (4149_CR21) 2021; 12
TK Ito (4149_CR70) 2009; 113
AJ Rostron (4149_CR29) 2021; 27
D Szklarczyk (4149_CR42) 2019; 47
Y Su (4149_CR12) 2022; 185
M Antonelli (4149_CR8) 2022; 399
J Hugon (4149_CR60) 2022; 269
A Dotan (4149_CR10) 2022; 21
SM Lam (4149_CR28) 2021; 3
S Pesce (4149_CR69) 2016; 7
T Shu (4149_CR39) 2020; 53
MAY Al-Nesf (4149_CR26) 2022; 13
A Shafi (4149_CR45) 2019; 19
D Castanares-Zapatero (4149_CR1) 2022; 54
4149_CR61
M Boldrini (4149_CR62) 2021
MA Patel (4149_CR5) 2023; 29
M Asaduzzaman (4149_CR65) 2018; 167
BB Sun (4149_CR44) 2018; 558
MA Ellul (4149_CR63) 2020; 19
Aj Portuguez (4149_CR57) 2022; 50
D Mathew (4149_CR49) 2020; 369
P Vedula (4149_CR25) 2022; 10
M Lundberg (4149_CR35) 2011; 39
BK Patterson (4149_CR72) 2022; 10
DD Fraser (4149_CR14) 2020; 2
J Couzin-Frankel (4149_CR9) 2022; 375
H Ledford (4149_CR11) 2022; 608
K Brown (4149_CR2) 2022; 22
LA Lupisella (4149_CR34) 2022
BK Patterson (4149_CR71) 2021; 28
SA Williams (4149_CR41) 2019; 25
D Mathew (4149_CR31) 2020; 369
A Silvin (4149_CR52) 2020; 182
E Akoumianaki (4149_CR74) 2021; 12
EAMC Adang (4149_CR79) 2023; 23
D Memon (4149_CR24) 2021; 13
AG Laing (4149_CR32) 2020; 26
CM Rice (4149_CR53) 2022
MA Patel (4149_CR4) 2022; 28
D Feyaerts (4149_CR27) 2021
Z Al-Aly (4149_CR6) 2021; 594
ZW Liu (4149_CR56) 2021
C Iosef (4149_CR30) 2023; 27
Z Zeng (4149_CR76) 2022; 9
PL Møller (4149_CR37) 2021; 8
AJ Wilk (4149_CR19) 2020; 26
E Dong (4149_CR15) 2020; 20
M Robertson (4149_CR75) 2002; 71
Y Xie (4149_CR66) 2022; 28
Z Zeng (4149_CR67) 2022; 9
JJ Kovarik (4149_CR77) 2023; 26
K Dendoncker (4149_CR58) 2019; 116
ML Meizlish (4149_CR55) 2021; 5
MR Filbin (4149_CR22) 2021; 2
AG Laing (4149_CR50) 2020; 26
A Kruger (4149_CR20) 2022; 21
A Nalbandian (4149_CR16) 2021; 27
Z Al-Aly (4149_CR18) 2022; 28
SM Parikh (4149_CR51) 2017; 24
PS Arunachalam (4149_CR36) 2020; 369
S Draghici (4149_CR43) 2007; 17
A Ring (4149_CR68) 2020; 20
SJ Yong (4149_CR7) 2022; 32
S Sinha (4149_CR54) 2022; 28
AM Newman (4149_CR48) 2015; 12
4149_CR3
J Zhao (4149_CR38) 2022; 16
Morikawa (4149_CR59) 2013; 32
M Witkowski (4149_CR78) 2021; 600
References_xml – volume: 27
  start-page: 141
  issue: 1
  year: 2023
  ident: 4149_CR30
  publication-title: J Cell Mol Med.
  doi: 10.1111/jcmm.17622
– volume: 25
  start-page: 1851
  issue: 12
  year: 2019
  ident: 4149_CR41
  publication-title: Nat Med
  doi: 10.1038/s41591-019-0665-2
– volume: 13
  start-page: 3387
  issue: 1
  year: 2022
  ident: 4149_CR64
  publication-title: Nat Commun
  doi: 10.1038/s41467-022-30932-1
– volume: 3
  start-page: 909
  issue: 7
  year: 2021
  ident: 4149_CR28
  publication-title: Nat Metab
  doi: 10.1038/s42255-021-00425-4
– volume: 369
  start-page: 8511
  issue: 6508
  year: 2020
  ident: 4149_CR49
  publication-title: Science
  doi: 10.1126/science.abc8511
– volume: 600
  start-page: 295
  year: 2021
  ident: 4149_CR78
  publication-title: Nature
  doi: 10.1038/s41586-021-04142-6
– volume: 21
  start-page: 103071
  issue: 5
  year: 2022
  ident: 4149_CR10
  publication-title: Autoimmun Rev
  doi: 10.1016/j.autrev.2022.103071
– volume: 608
  start-page: 258
  issue: 7922
  year: 2022
  ident: 4149_CR11
  publication-title: Nature
  doi: 10.1038/d41586-022-02140-w
– volume: 3
  start-page: e0369
  issue: 3
  year: 2021
  ident: 4149_CR33
  publication-title: Crit Care Explor
  doi: 10.1097/CCE.0000000000000369
– volume: 269
  start-page: 44
  issue: 1
  year: 2022
  ident: 4149_CR60
  publication-title: J Neurol
  doi: 10.1007/s00415-021-10655-x
– ident: 4149_CR3
– volume: 2
  start-page: e0144
  issue: 6
  year: 2020
  ident: 4149_CR14
  publication-title: Crit Care Explor
  doi: 10.1097/CCE.0000000000000144
– volume: 399
  start-page: 2263
  issue: 10343
  year: 2022
  ident: 4149_CR8
  publication-title: Lancet
  doi: 10.1016/S0140-6736(22)00941-2
– ident: 4149_CR61
– volume: 71
  start-page: 173
  issue: 2
  year: 2002
  ident: 4149_CR75
  publication-title: J Leukoc Biol
  doi: 10.1189/jlb.71.2.173
– volume: 55
  start-page: 542
  issue: 3
  year: 2022
  ident: 4149_CR13
  publication-title: Immunity
  doi: 10.1016/j.immuni.2022.01.017
– volume: 19
  start-page: 159
  issue: 10
  year: 2019
  ident: 4149_CR45
  publication-title: Front Genet
  doi: 10.3389/fgene.2019.00159
– volume: 29
  start-page: 26
  issue: 1
  year: 2023
  ident: 4149_CR5
  publication-title: Mol Med
  doi: 10.1186/s10020-023-00610-z
– volume: 32
  start-page: e2315
  issue: 4
  year: 2022
  ident: 4149_CR7
  publication-title: Rev Med Virol
  doi: 10.1002/rmv.2315
– volume: 47
  start-page: D607
  issue: D1
  year: 2019
  ident: 4149_CR42
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gky1131
– volume: 54
  start-page: 1473
  issue: 1
  year: 2022
  ident: 4149_CR1
  publication-title: Ann Med
  doi: 10.1080/07853890.2022.2076901
– volume: 7
  start-page: 414
  issue: 7
  year: 2016
  ident: 4149_CR69
  publication-title: Front Immunol
– volume: 26
  start-page: 1623
  year: 2020
  ident: 4149_CR32
  publication-title: Nat Med
  doi: 10.1038/s41591-020-1038-6
– year: 2021
  ident: 4149_CR56
  publication-title: Front Immunol
  doi: 10.3389/fimmu.12:810286.10.3389/fimmu.2021.810286
– volume: 14
  start-page: e241485
  year: 2021
  ident: 4149_CR17
  publication-title: BMJ Case Rep
  doi: 10.1136/bcr-2020-241485
– volume: 21
  start-page: 190
  issue: 1
  year: 2022
  ident: 4149_CR20
  publication-title: Cardiovasc Diabeto
  doi: 10.1186/s12933-022-01623-4
– volume: 53
  start-page: 1108
  issue: 5
  year: 2020
  ident: 4149_CR39
  publication-title: Immunity
  doi: 10.1016/j.immuni.2020.10.008
– volume: 21
  start-page: 198
  year: 2020
  ident: 4149_CR73
  publication-title: Respir Res
  doi: 10.1186/s12931-020-01462-5
– volume: 116
  start-page: 12942
  issue: 26
  year: 2019
  ident: 4149_CR58
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.1821565116
– volume: 369
  start-page: 1210
  issue: 6508
  year: 2020
  ident: 4149_CR36
  publication-title: Science
  doi: 10.1126/science.abc6261
– volume: 369
  start-page: 8511
  issue: 6508
  year: 2020
  ident: 4149_CR31
  publication-title: Science
  doi: 10.1126/science.abc8511
– volume: 10
  start-page: 807149
  year: 2022
  ident: 4149_CR25
  publication-title: Front Cell Dev Biol
  doi: 10.3389/fcell.2022.807149
– volume: 26
  start-page: 105717
  issue: 1
  year: 2023
  ident: 4149_CR77
  publication-title: iScience
  doi: 10.1016/j.isci.2022.105717
– volume: 28
  start-page: 583
  year: 2022
  ident: 4149_CR66
  publication-title: Nat Med
  doi: 10.1038/s41591-022-01689-3
– year: 2022
  ident: 4149_CR34
  publication-title: Semin Immunol
  doi: 10.1016/j.smim.2022.101602
– volume: 375
  start-page: 364
  issue: 6579
  year: 2022
  ident: 4149_CR9
  publication-title: Science
  doi: 10.1126/science.ada0536
– volume: 12
  start-page: 745634
  year: 2021
  ident: 4149_CR74
  publication-title: Front Physiol
  doi: 10.3389/fphys.2021.745634
– year: 2021
  ident: 4149_CR27
  publication-title: bioRxiv
  doi: 10.1016/j.xcrm.2022.100680
– volume: 185
  start-page: 881
  issue: 5
  year: 2022
  ident: 4149_CR12
  publication-title: Cell
  doi: 10.1016/j.cell.2022.01.014
– volume: 13
  start-page: e14532
  issue: 8
  year: 2021
  ident: 4149_CR24
  publication-title: EMBO Mol Med
  doi: 10.15252/emmm.202114532
– volume: 16
  start-page: e2200031
  issue: 5
  year: 2022
  ident: 4149_CR38
  publication-title: Proteomics Clin Appl
  doi: 10.1002/prca.202200031
– volume: 28
  start-page: 122
  issue: 1
  year: 2022
  ident: 4149_CR4
  publication-title: Molec Med
  doi: 10.1186/s10020-022-00548-8
– volume: 13
  start-page: 946
  issue: 1
  year: 2022
  ident: 4149_CR26
  publication-title: Nat Commun
  doi: 10.1038/s41467-022-28639-4
– volume: 39
  start-page: e102
  issue: 15
  year: 2011
  ident: 4149_CR35
  publication-title: Nucl Acid Res
  doi: 10.1093/nar/gkr424
– volume: 50
  start-page: 6702
  issue: 12
  year: 2022
  ident: 4149_CR57
  publication-title: Nucl Ac Res
  doi: 10.1093/nar/gkac488
– volume: 27
  start-page: 904
  issue: 5
  year: 2021
  ident: 4149_CR29
  publication-title: Nat Med
  doi: 10.1038/s41591-021-01329-2
– volume: 594
  start-page: 259
  issue: 7862
  year: 2021
  ident: 4149_CR6
  publication-title: Nature
  doi: 10.1038/s41586-021-03553-9
– volume: 2
  start-page: 100287
  issue: 5
  year: 2021
  ident: 4149_CR23
  publication-title: Cell Rep Med
  doi: 10.1016/j.xcrm.2021.100287
– volume: 8
  start-page: 652584
  year: 2021
  ident: 4149_CR37
  publication-title: Front Cardiovasc Med
  doi: 10.3389/fcvm.2021.652584
– volume: 20
  start-page: 533
  year: 2020
  ident: 4149_CR15
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(20)30120-1
– volume: 26
  start-page: 1070
  year: 2020
  ident: 4149_CR19
  publication-title: Nat Med
  doi: 10.1038/s41591-020-0944-y
– volume: 24
  start-page: 432
  issue: 5
  year: 2017
  ident: 4149_CR51
  publication-title: Curr Oppinion Hematol
  doi: 10.1097/MOH.0000000000000361
– volume: 10
  start-page: 746021
  issue: 12
  year: 2022
  ident: 4149_CR72
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2021.746021
– volume: 5
  start-page: 1164
  issue: 5
  year: 2021
  ident: 4149_CR55
  publication-title: Blood Adv
  doi: 10.1182/bloodadvances.2020003568
– year: 2022
  ident: 4149_CR47
  publication-title: Lancet Digit Health
  doi: 10.1016/S2589-7500(22)00048-6
– volume: 27
  start-page: 601
  issue: 4
  year: 2021
  ident: 4149_CR16
  publication-title: Nat Med Nat Med
  doi: 10.1038/s41591-021-01283-z
– volume: 167
  start-page: 605
  issue: 2
  year: 2018
  ident: 4149_CR65
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-017-4633-6
– volume: 2
  start-page: e0189
  issue: 9
  year: 2020
  ident: 4149_CR40
  publication-title: Crit Care Explor.
  doi: 10.1097/CCE.0000000000000189
– volume: 28
  start-page: 700782
  issue: 12
  year: 2021
  ident: 4149_CR71
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2021.700782
– year: 2022
  ident: 4149_CR53
  publication-title: medRix
  doi: 10.1101/2022.03.23.22272828
– volume: 19
  start-page: 767
  year: 2020
  ident: 4149_CR63
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(20)30221-0
– volume: 12
  start-page: 453
  issue: 5
  year: 2015
  ident: 4149_CR48
  publication-title: Nat Methods
  doi: 10.1038/nmeth.3337
– volume: 28
  start-page: 201
  issue: 1
  year: 2022
  ident: 4149_CR54
  publication-title: Nat Med
  doi: 10.1038/s41591-021-01576-3
– volume: 113
  start-page: 2363
  issue: 10
  year: 2009
  ident: 4149_CR70
  publication-title: Blood
  doi: 10.1182/blood-2008-08-172742
– volume: 9
  start-page: 12
  issue: 1
  year: 2022
  ident: 4149_CR67
  publication-title: Genes Dis
  doi: 10.1016/j.gendis.2021.08.004
– volume: 10
  start-page: 4188
  issue: 1
  year: 2020
  ident: 4149_CR46
  publication-title: Sci Rep
  doi: 10.1038/s41598-020-60981-9
– volume: 9
  start-page: 12
  issue: 1
  year: 2022
  ident: 4149_CR76
  publication-title: Genes Dis
  doi: 10.1016/j.gendis.2021.08.004
– volume: 12
  start-page: 780
  issue: 8
  year: 2021
  ident: 4149_CR21
  publication-title: Cell Syst
  doi: 10.1016/j.cels.2021.05.005
– volume: 26
  start-page: 1623
  year: 2020
  ident: 4149_CR50
  publication-title: Nat Med
  doi: 10.1038/s41591-020-1038-6
– volume: 17
  start-page: 1537
  issue: 10
  year: 2007
  ident: 4149_CR43
  publication-title: Genome Res
  doi: 10.1101/gr.6202607
– volume: 182
  start-page: 1401
  year: 2020
  ident: 4149_CR52
  publication-title: Cell
  doi: 10.1016/j.cell.2020.08.002
– volume: 2
  start-page: 100287
  issue: 5
  year: 2021
  ident: 4149_CR22
  publication-title: Cell Rep Med
  doi: 10.1016/j.xcrm.2021.100287
– year: 2021
  ident: 4149_CR62
  publication-title: JAMA Psychiat
  doi: 10.1001/jamapsychiatry.2021.0500
– volume: 32
  start-page: 1609
  year: 2013
  ident: 4149_CR59
  publication-title: Oncogene
  doi: 10.1038/onc.2012.191
– volume: 558
  start-page: 73
  issue: 7708
  year: 2018
  ident: 4149_CR44
  publication-title: Nature
  doi: 10.1038/s41586-018-0175-2
– volume: 22
  start-page: 10322
  issue: 399
  year: 2022
  ident: 4149_CR2
  publication-title: Lancet
– volume: 28
  start-page: 1461
  issue: 7
  year: 2022
  ident: 4149_CR18
  publication-title: Nat Med
  doi: 10.1038/s41591-022-01840-0
– volume: 20
  start-page: 1076
  issue: 1
  year: 2020
  ident: 4149_CR68
  publication-title: BMC Cancer
  doi: 10.1186/s12885-020-07573-y
– volume: 23
  start-page: 2473
  issue: 5
  year: 2023
  ident: 4149_CR79
  publication-title: Sensors
  doi: 10.3390/s23052473
SSID ssj0024549
Score 2.511876
Snippet Long-COVID occurs after SARS-CoV-2 infection and results in diverse, prolonged symptoms. The present study aimed to unveil potential mechanisms, and to inform...
Aims Long-COVID occurs after SARS-CoV-2 infection and results in diverse, prolonged symptoms. The present study aimed to unveil potential mechanisms, and to...
AimsLong-COVID occurs after SARS-CoV-2 infection and results in diverse, prolonged symptoms. The present study aimed to unveil potential mechanisms, and to...
Abstract Aims Long-COVID occurs after SARS-CoV-2 infection and results in diverse, prolonged symptoms. The present study aimed to unveil potential mechanisms,...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 377
SubjectTerms Analysis
Angiopoietin
Angiotensin
Bioinformatics
Biomarkers
Brain
CD56 antigen
Chemokines
Citrulline
Clustering
COVID-19
Disease
Elastase
Genes
Genetic engineering
Geospatial data
Histones
Humans
Hypoxia
Infections
Laboratories
Leukocytes (neutrophilic)
Long COVID
Medical research
Natural killer cells
Neutrophils
Phenotypes
Plasma
Post-Acute COVID-19 Syndrome
Prospective Studies
Protein expression
Proteins
Proteome
Proteomes
Proteomics
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Signal transduction
Software
Therapeutic targets
Vascular endothelial growth factor
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4k2gICMhcUBR49iO7WMprLaI14Gi3iy_Akg0qdjtL-CPM2Mnq42Q4MI1dqTY8_hm4vE3hDyPrYlNiKFmPEKCEhNS3gYwvKA6pUxuWYjVFh-69Zl4ey7P91p9YU1YoQcuG3cEAKM8axMgoxGxDdoI1_vGOx11bGP2voB5czI1s-xB2jNfkdHd0QZQDRwC4FPdCMgJarOAoczW_6dP3gOlZcHkHgKtbpGbU-hIj8sn3ybX0nCHXH8_HY7fJb8-QSR84WimXhgvEh17-m4cvtYnH7-cvqYTg-qG4ik11kFt6Pp0VeerIxB20lKTOtaX2MenT4URnE4HOBT_19JypZKOA_XYWYK6IVLsiL2lCI8o4nvkbPXm88m6nnos1EF2Yls7k1yXpOwj5F2RBe77FIVnvZJBd1o6GaVgikUI1bh30SgTffCp4dzFwDm_Tw6GcUgPCdWh0Qrwv2-jF8oFLXpvmGMJGYVUUBVh85bbMBGQYx-MHzYnIrqzRUwWxGSzmKypyMvdO5eFfuOvs1-hJHczkTo7PwCFspNC2X8pVEVeoB5YNHD4vOCmewqwSKTKssdKQpgIYQ2vyOFiJhhmWA7PmmQnx7CxkOEqxgCBWEWe7YbxTSx2G9J4leeIDiJfLivyoCjebkkcPbKRuiJ6oZKLNS9Hhu_fMm04hJJScd0--h-79JjcaLM5dQDkh-Rg-_MqPYHwbOufZkv8DSBXN14
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIgL4k1KQUZC4oCirmM7dk6oFFZbxOtA0d4sv9Ii0WTbbH8Bf5wZx7tthNRr7Ehx5vWNPf6GkDehasLMB18yHiBBCREpbz0Ynle1Uk1qWYjVFt_qxbH4vJTLvOE25LLKjU9Mjjr0HvfI9yE1UIyB6bL3q_MSu0bh6WpuoXGb3EHqMizpUsurhEtA8rO5KKPr_QFiG7gFiFLlTEBmUDaTYJQ4-__3zNdC07Rs8locmj8g9zOApAejxB-SW7F7RO5-zUfkj8nfH4CHzyxNBAz9WaR9S7_03Ul5-P3X0UeaeVQHimfVWA010MXRvEwXSAB80rEytS9X2M2njSMvOM3HOBR3bel4sZL2HXXYX4LaLlDsi72mGCRR0E_I8fzTz8NFmTstlF7WYl3aJto6StkGyL4C89y1MQjHWiW9rrW0MkjBFAsA2LizoVFNcN7FGec2eM75U7LT9V18Tqj2M60ABbRVcEJZr0XrGmZZRF4h5VVB2OaXG59pyLEbxh-T0hFdm1FMBsRkkphMU5B323dWIwnHjbM_oCS3M5FAOz3oL05MtkcDuEU5VkUAXI0IldeNsK2bOauDDlWoCvIW9cCgmcPneZtvK8AikTDLHCgJYBHADS_I3mQmmKefDm80yWT3MJgrZS7I6-0wvoklb13sL9McUQP-5bIgz0bF2y6Jo18GfS-InqjkZM3Tke73aSIPB0ApFdfV7s3f9YLcq5Kh1BCo98jO-uIyvgT4tXavko39A3vrLsE
  priority: 102
  providerName: ProQuest
Title Plasma proteome of Long-COVID patients indicates HIF-mediated vasculo-proliferative disease with impact on brain and heart function
URI https://www.ncbi.nlm.nih.gov/pubmed/37301958
https://www.proquest.com/docview/2827117621
https://www.proquest.com/docview/2824695135
https://pubmed.ncbi.nlm.nih.gov/PMC10257382
https://doaj.org/article/4157b12e66394d2c894afb0ba8d8d2d2
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELb6kKpeEG8CZWUkJA4osImT2D4g1C1dbREtVcWiFRfLrxSkNim7WwnO_HFmnGTZiIoDlz3EtrS2v8l8E4-_IeS5S6UbWmfjhDkIUJxHyVsLhmd5wbkMJQsx2-KkmEyz97N8tkG6ckftAi5uDO2wntR0fvHqx_efb8Hg3wSDF8XrBfgsMHfwPvEwA8Yfy02yDZ6Jo6EeZ-KP9h4EQ93FmRvH7ZIdhpCXWAF-zU8FOf-_X9prXqufUbnmosa3ya2WW9L9Bgx3yIav7pKd4_b0_B75dQpU-VLToM1QX3pal_RDXZ3HBx8_H72jrcTqguIxNiZKLejkaByHuyXAS2mTtFrHV1jop_SNZDhtT3goftClzZ1LWlfUYOkJqitHsWT2kqL_RAzcJ9Px4aeDSdwWYYhtXmTLWEuvC5_npYPAzCWWmdK7zCQlz60oRK5zl-NSO-ByzGgnuXTGGj9kTDvLGHtAtqq68o8IFXYoOBCEMnUm49qKrDQy0YlHySFueUSSbsmVbRXKsVDGhQqRiihUs2MKdkyFHVMyIi9XY64afY5_9h7hTq56orZ2eFDPz1VrqgooDTdJ6oGLycylVshMl2ZotHDCpS6NyAvEgUJMwt-zur3IAJNELS21z3PgkcB7WET2ej3Bcm2_uUOS6oCvIATmSQIuKonIs1UzjsRsuMrX16FPVgA1ZnlEHjbAW02pw29ERA-SvTn3W6pvX4OuOHDNnDORPv7_oU_IbhrsqQD_vke2lvNr_xRY29IMyCaf8QHZHh2enJ4NwrePQTBP-D0bffkN2qZEBg
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELaqVgIuiDeBAkYCcUBR10kc2weE-lrt0u1SoRb15vqVgkSTpbsV4sz_4Tcyk8e2EVJvvcaOFGde39jjbwh54xPlB867mKUeEhQfkPLWgeE5kQuh6paFWG0xzUdH2adjfrxC_nZ3YbCssvOJtaP2lcM98g1IDQRjYLrs4-xnjF2j8HS1a6HRqMVe-P0LUrb5h_EOyPdtkgx3D7dHcdtVIHY8zxaxUcHkgfPCQ6bhmUttEXxmWSG4k7nkhnueMcE8gJPUGq-E8tbZMEhT412KG6Dg8teyFFKZVbK2tTs9-HLJ7gfpVnc1R-Ybc4im4IggLsaDDHKRWPXCX90l4P9YcCUY9gs1r0S-4T1yt4WsdLPRsftkJZQPyK399lD-IflzAAj8zNCa8qE6C7Qq6KQqT-Ptz1_HO7Rlbp1TPB3H-qs5HY2HcX1lBeAubWphq3iG_YOK0DCR0_bgiOI-MW2uctKqpBY7WlBTeoqduBcUwzKq1iNydCNSeExWy6oMTwmVbiAF4I4i8TYTxsmssIoZFpDJSDgREdb9cu1a4nPsv_FD1wmQzHUjJg1i0rWYtIrI--U7s4b249rZWyjJ5Uyk7K4fVOenuvUAGpCSsCwJAPFU5hMnVWYKO7BGeukTn0TkHeqBRscCn-dMez8CFokUXXpTcICnAKfSiKz3ZoJDcP3hTpN065Dm-tJ8IvJ6OYxvYpFdGaqLek6WA-JOeUSeNIq3XFKKkUBxGRHZU8nemvsj5fdvNV05QFguUpk8u_67XpHbo8P9iZ6Mp3vPyZ2kNpocYMI6WV2cX4QXAP4W9mVrcZSc3LSR_wPJd26-
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Plasma+proteome+of+Long-COVID+patients+indicates+HIF-mediated+vasculo-proliferative+disease+with+impact+on+brain+and+heart+function&rft.jtitle=Journal+of+translational+medicine&rft.au=Iosef%2C+Cristiana&rft.au=Knauer%2C+Michael+J.&rft.au=Nicholson%2C+Michael&rft.au=Van+Nynatten%2C+Logan+R.&rft.date=2023-06-10&rft.pub=BioMed+Central&rft.eissn=1479-5876&rft.volume=21&rft_id=info:doi/10.1186%2Fs12967-023-04149-9&rft_id=info%3Apmid%2F37301958&rft.externalDocID=PMC10257382
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1479-5876&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1479-5876&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1479-5876&client=summon